CytomX Therapeutics (CTMX) News Today $1.02 +0.06 (+6.64%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025May 5 at 8:00 AM | globenewswire.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Acquired by JPMorgan Chase & Co.JPMorgan Chase & Co. increased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 288,736.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 811,630 shares of the biotechnology compApril 30, 2025 | marketbeat.comCorcept Therapeutics to Report Q1 Earnings: What's in the Cards?April 29, 2025 | msn.comCytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual MeetingApril 28, 2025 | globenewswire.comBrokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $4.77April 27, 2025 | americanbankingnews.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and three have given a buy rating toApril 26, 2025 | marketbeat.comBeam Therapeutics to Report Q1 Earnings: What's in the Cards?April 25, 2025 | msn.comAmicus Therapeutics to Report Q1 Earnings: What's in the Cards?April 23, 2025 | msn.comAltium Capital Management LLC Trims Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX)Altium Capital Management LLC decreased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 48.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 467,491 shares of the biotechnology compaApril 20, 2025 | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on CytomX Therapeutics (CTMX)April 15, 2025 | markets.businessinsider.comCytomX Therapeutics assumed with an Overweight at Piper SandlerApril 15, 2025 | markets.businessinsider.comCytomX Therapeutics participates in a conference call with JPMorganApril 2, 2025 | markets.businessinsider.comStockNews.com Downgrades CytomX Therapeutics (NASDAQ:CTMX) to HoldStockNews.com cut CytomX Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.April 1, 2025 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Up 91.5% in MarchCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 9,000,000 shares, an increase of 91.5% from the February 28th total of 4,700,000 shares. Approximately 12.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,790,000 shares, the short-interest ratio is presently 5.0 days.March 29, 2025 | marketbeat.comInsider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Sells 19,512 Shares of StockCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) SVP Marcia Belvin sold 19,512 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $0.60, for a total transaction of $11,707.20. Following the completion of the sale, the senior vice president now directly owns 248,636 shares in the company, valued at $149,181.60. This trade represents a 7.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.March 21, 2025 | marketbeat.comSean A. Mccarthy Sells 37,656 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) StockCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CEO Sean A. Mccarthy sold 37,656 shares of CytomX Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $0.60, for a total value of $22,593.60. Following the sale, the chief executive officer now owns 995,195 shares in the company, valued at $597,117. This represents a 3.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 21, 2025 | marketbeat.comInsider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Sells 19,512 Shares of StockMarch 21, 2025 | insidertrades.comCytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal yearMarch 14, 2025 | uk.investing.comCytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by StockNews.comStockNews.com raised shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a research report on Monday.March 11, 2025 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comCytomX Therapeutics (NASDAQ:CTMX) Given "Outperform" Rating at WedbushWedbush reaffirmed an "outperform" rating and set a $5.00 price objective on shares of CytomX Therapeutics in a report on Friday.March 8, 2025 | marketbeat.comCytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy NowMarch 7, 2025 | insidermonkey.comCytomX Therapeutics Announces 2024 Financial Results and Provides Business UpdateMarch 7, 2025 | markets.businessinsider.comCytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comCytomX Therapeutics Announces 2024 Financial Results and Provides Business UpdateMarch 6, 2025 | globenewswire.comCytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare ConferenceMarch 5, 2025 | globenewswire.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by BrokeragesShares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and three have assigneMarch 5, 2025 | marketbeat.comCytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on ThursdayCytomX Therapeutics (NASDAQ:CTMX) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=351571)March 1, 2025 | marketbeat.comCytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025February 27, 2025 | globenewswire.comCytomX Therapeutics (NASDAQ:CTMX) Share Price Crosses Below 50-Day Moving Average - Here's What HappenedCytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50-Day Moving Average - What's Next?February 26, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below 50 Day Moving Average - Should You Sell?CytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below 50 Day Moving Average - Here's What HappenedFebruary 18, 2025 | marketbeat.comCTMX stock touches 52-week low at $0.76 amid market challengesFebruary 11, 2025 | msn.comAssenagon Asset Management S.A. Sells 1,044,318 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)Assenagon Asset Management S.A. reduced its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 63.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 599,850 shares of the biotechnology company'January 25, 2025 | marketbeat.comShort Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Drops By 13.4%CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 4,800,000 shares, a decline of 13.4% from the December 15th total of 5,540,000 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is currently 3.9 days.January 19, 2025 | marketbeat.comBay Area biotech firm CytomX, once worth $2.3 billion, lays off 40% of staffJanuary 15, 2025 | msn.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of "Moderate Buy" by AnalystsShares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and three have given a buy ratinJanuary 14, 2025 | marketbeat.comCytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)January 8, 2025 | markets.businessinsider.comCytomX Therapeutics Inc.: CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate UpdateJanuary 7, 2025 | finanznachrichten.deCytomX Therapeutics (CTMX) Gets a Buy from BarclaysJanuary 7, 2025 | markets.businessinsider.comCytomX Therapeutics (CTMX) Receives a Buy from WedbushJanuary 7, 2025 | markets.businessinsider.comCytomX falls after portfolio shakeup, job cutsJanuary 7, 2025 | msn.comCytomX Therapeutics to Cut 40% of WorkforceJanuary 7, 2025 | marketwatch.comCytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate UpdateJanuary 7, 2025 | markets.businessinsider.comPeninsula biotech to lay off 40% of workforce as it restructuresJanuary 7, 2025 | bizjournals.comCytomX Therapeutics (NASDAQ:CTMX) Receives "Neutral" Rating from HC WainwrightHC Wainwright reissued a "neutral" rating on shares of CytomX Therapeutics in a research report on Tuesday.January 7, 2025 | marketbeat.comCytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate UpdateJanuary 6, 2025 | globenewswire.comShort Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Expands By 26.2%CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 5,540,000 shares, a growth of 26.2% from the November 30th total of 4,390,000 shares. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is presently 4.8 days.December 31, 2024 | marketbeat.comCytomX heading into ‘major catalyst year,’ says JonesResearchDecember 31, 2024 | markets.businessinsider.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from AnalystsCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have assignDecember 20, 2024 | marketbeat.com Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address CTMX Media Mentions By Week CTMX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTMX News Sentiment▼0.600.69▲Average Medical News Sentiment CTMX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTMX Articles This Week▼32▲CTMX Articles Average Week Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Fulcrum Therapeutics News Today Aura Biosciences News Today Atai Life Sciences News Today Cryoport News Today Astria Therapeutics News Today Terns Pharmaceuticals News Today Monte Rosa Therapeutics News Today Gossamer Bio News Today Aquestive Therapeutics News Today iTeos Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTMX) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.